Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors

Biochemistry

Volumn 54, Issue 1, 2015, Pages 22-31

  Rudolph, Johannes ^a   Xiao, Yao ^a   Pardi, Arthur ^a   Ahn, Natalie G ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; CONFORMATIONS; DISSOCIATION; ENZYME ACTIVITY; KINETICS; QUANTUM THEORY; RATE CONSTANTS;

ANTI-CANCER THERAPIES; CONFORMATIONAL SELECTION; DISSOCIATION RATE CONSTANT; ENZYME CONFORMATIONS; EXTRACELLULAR SIGNAL-REGULATED KINASE; MITOGEN ACTIVATED PROTEIN KINASE; QUANTUM CORRELATIONS; TARGETED THERAPEUTICS;

ENZYMES;

5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; FR 180204; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OLOMOUCINE; SCH772984; UNCLASSIFIED DRUG; VERTEX 1; VERTEX 11E; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISSOCIATION CONSTANT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; HETERONUCLEAR MULTIPLE QUANTUM COHERENCE; HYSTERESIS; LIGAND BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DOSE RESPONSE; METABOLISM; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; TIME FACTOR;

ANIMALS; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; RATS; TIME FACTORS;

EID: 84921312649     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi501101v     Document Type: Article

References (49)

1. Roberts, P. J. and Der, C. J. (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26, 3291-3310
2. Flaherty, K. T., Hodi, F. S., and Bastian, B. C. (2010) Mutation-driven drug development in melanoma Curr. Opin. Oncol. 22, 178-183
3. Solit, D. B. and Rosen, N. (2011) Resistance to BRAF inhibition in melanomas N. Engl. J. Med. 364, 772-774
4. Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, H. A., III, Falchook, G., Algazi, A., Lewis, K., Long, G. V., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K. B., Patel, K., and Weber, J. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N. Engl. J. Med. 367, 1694-1703
5. Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., Flaherty, L., Logan, T., Chmielowski, B., Lewis, K., Kee, D., Boasberg, P., Yin, M., Chan, I., Musib, L., Choong, N., Puzanov, I., and McArthur, G. A. (2014) Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: A phase 1b study Lancet Oncol. 15, 954-965
6. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M. K., Attar, N., Sazegar, H., Chodon, T., Nelson, S. F., McArthur, G., Sosman, J. A., Ribas, A., and Lo, R. S. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468, 973-977
7. Little, A. S., Balmanno, K., Sale, M. J., Newman, S., Dry, J. R., Hampson, M., Edwards, P. A. W., Smith, P. D., and Cook, S. J. (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells Sci. Signaling 4, ra17
8. Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., and Gilmer, T. M. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol. Cancer Ther. 11, 909-920
9. Shi, H., Moriceau, G., Kong, X., Lee, M. K., Lee, H., Koya, R. C., Ng, C., Chodon, T., Scolyer, R. A., Dahlman, K. B., Sosman, J. A., Kefford, R. F., Long, G. V., Nelson, S. F., Ribas, A., and Lo, R. S. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat. Commun. 3, 724
10. Morris, E. J., Jha, S., Restaino, C. R., Dayananth, P., Zhu, H., Cooper, A., Carr, D., Deng, Y., Jin, W., Black, S., Long, B., Liu, J., Dinunzio, E., Windsor, W., Zhang, R., Zhao, S., Angagaw, M. H., Pinheiro, E. M., Desai, J., Xiao, L., Shipps, G., Hruza, A., Wang, J., Kelly, J., Paliwal, S., Gao, X., Babu, B. S., Zhu, L., Daublain, P., Zhang, L., Lutterbach, B. A., Pelletier, M. R., Philippar, U., Siliphaivanh, P., Witter, D., Kirschmeier, P., Bishop, W. R., Hicklin, D., Gilliland, D. G., Jayaraman, L., Zawel, L., Fawell, S., and Samatar, A. A. (2013) Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors Cancer Discovery 3, 742-750
11. Hatzivassiliou, G., Liu, B., OBrien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., Toy, K., Ha, C., Zhou, W., Song, K., Friedman, L. S., Amler, L. C., Hampton, G. M., Moffat, J., Belvin, M., and Lackner, M. R. (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors Mol. Cancer Ther. 11, 1143-1153
12. Aronov, A. M., Tang, Q., Martinez-Botella, G., Bemis, G. W., Cao, J., Chen, G., Ewing, N. P., Ford, P. J., Germann, U. A., Green, J., Hale, M. R., Jacobs, M., Janetka, J. W., Maltais, F., Markland, W., Namchuk, M. N., Nanthakumar, S., Poondru, S., Straub, J., ter Haar, E., and Xie, X. (2009) Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control J. Med. Chem. 52, 6362-6368
13. Zhang, F., Strand, A., Robbins, D., Cobb, M. H., and Goldsmith, E. J. (1994) Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution Nature 367, 704-711
14. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., and Goldsmith, E. J. (1997) Activation mechanism of the MAP kinase ERK2 by dual phosphorylation Cell 90, 859-869
15. Prowse, C. N. and Lew, J. (2001) Mechanism of Activation of ERK2 by Dual Phosphorylation J. Biol. Chem. 276, 99-103
16. Xiao, Y., Lee, T., Latham, M. P., Warner, L. R., Tanimoto, A., Pardi, A., and Ahn, N. G. (2014) Phosphorylation releases constraints to domain motion in ERK2 Proc. Natl. Acad. Sci. U.S.A. 111, 2506-2511
17. Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., and Gray, N. S. (2014) Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS Chem. Biol. 9, 1230-1241
18. Lovering, F., McDonald, J., Whitlock, G. A., Glossop, P. A., Phillips, C., Bent, A., Sabnis, Y., Ryan, M., Fitz, L., Lee, J., Chang, J. S., Han, S., Kurumbail, R., and Thorarensen, A. (2012) Identification of type-II inhibitors using kinase structures Chem. Biol. Drug Des. 80, 657-664
19. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64, 6652-6659
20. Palmieri, L. and Rastelli, G. (2013) αC helix displacement as a general approach for allosteric modulation of protein kinases Drug Discovery Today 18, 407-414
21. Copeland, R. A., Pompliano, D. L., and Meek, T. D. (2006) Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 5, 730-739
22. Copeland, R. A. (2011) Conformational adaptation in drug-target interactions and residence time Future Med. Chem. 3, 1491-1501
23. Francis, D. M. 2011, Resting and active states of the ERK2:HePTP complex J. Am. Chem. Soc. 133, 17138-17141
24. Shapiro, P. S. 1998, Activation of the MKK/ERK pathway during somatic cell mitosis: Direct interactions of active ERK with kinetochores and regulation of the mitotic 3F3/2 phosphoantigen J. Cell Biol. 142, 1533-1545
25. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 6, 277-293
26. Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., Markley, J. L., Ionides, J., and Laue, E. D. (2005) The CCPN data model for NMR spectroscopy: Development of a software pipeline Proteins 59, 687-696
27. Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisá, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., and Goldsmith, E. J. (1998) Structural basis of inhibitor selectivity in MAP kinases Structure 6, 1117-1128
28. Ohori, M., Kinoshita, T., Okubo, M., Sato, K., Yamazaki, A., Arakawa, H., Nishimura, S., Inamura, N., Nakajima, H., Neya, M., Miyake, H., and Fujii, T. (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex Biochem. Biophys. Res. Commun. 336, 357-363
29. Aronov, A. M., Baker, C., Bemis, G. W., Cao, J., Chen, G., Ford, P. J., Germann, U. A., Green, J., Hale, M. R., Jacobs, M., Janetka, J. W., Maltais, F., Martinez-Botella, G., Namchuk, M. N., Straub, J., Tang, Q., and Xie, X. (2007) Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors J. Med. Chem. 50, 1280-1287
30. Chaikuad, A., Tacconi, E. M. C., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., and Knapp, S. (2014) A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics Nat. Chem. Biol. 10, 853-860
31. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: Visual Molecular Dynamics J. Mol. Graphics 14, 33-38
32. Fernandes, N., Bailey, D. E., VanVranken, D. L., and Allbritton, N. L. (2007) Use of docking peptides to design modular substrates with high efficienty for mitogen-activated protein kinase extracellular signal-regulated kinase ACS Chem. Biol. 2, 665-673
33. Lee, S., Warthaka, M., Yan, C., Kaoud, T., Ren, P., and Dalby, K. N. (2011) Examining docking interactions on Erk2 with modular peptide substrates Biochemistry 50, 9500-9510
34. Morrison, J. F. and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors Adv. Enzymol. 61, 201-301
35. Cha, S. (1975) Tight-binding inhibitors I: Kinetic behavior Biochem. Pharmacol. 24, 2177-2185
36. Copeland, R. A. (2013) Evaluation of enzyme inhibitors in drug discovery, John Wiley & Sons, Hoboken, NJ.
37. Morrison, J. F. (1969) Kinetics of the reversible inhibition of enzyme-catalyzed reactions by tight-binding inhibitors Biochim. Biophys. Acta 185, 269-286
38. Lewandowicz, A., Tyler, P. C., Evans, G. B., Furneaux, R. H., and Schramm, V. L. (2003) Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase J. Biol. Chem. 278, 31465-31468
39. Hari, S. B., Merritt, E. A., and Maly, D. J. (2013) Sequence determinants of a specific inactive protein kinase conformation Chem. Biol. 20, 806-815
40. Millan, D. S., Bunnage, M. E., Burrows, J. L., Butcher, K. J., Dodd, P. G., Evans, T. J., Fairman, D. A., Hughes, S. J., Kilty, I. C., Lemaitre, A., Lewthwaite, R. A., Mahnke, A., Mathias, J. P., Philip, J., Smith, R. T., Stefaniak, M. H., Yeadon, M., and Phillips, C. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease J. Med. Chem. 54, 7797-7814
41. Yan, S. B., Peek, V. L., Ajamie, R., Buchanan, S. G., Graff, J. R., Heidler, S. A., Hui, Y. H., Huss, K. L., Konicek, B. W., Manro, J. R., Shih, C., Stewart, J. A., Stewart, T. R., Stout, S. L., Uhlik, M. T., Um, S. L., Wang, Y., Wu, W., Yan, L., Yang, W. J., Zhong, B., and Walgren, R. A. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models Invest. New Drugs 31, 833-844
42. Lesuisse, D., Mauger, J., Nemecek, C., Maignan, S., Boiziau, J., Harlow, G., Hittinger, A., Ruf, S., Strobel, H., Nair, A., Ritter, K., Malleron, J. L., Dagallier, A., El-Ahmad, Y., Guilloteau, J. P., Guizani, H., Bouchard, H., and Venot, C. (2011) Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors Bioorg. Med. Chem. Lett. 21, 2224-2228
43. Iwata, H., Imamura, S., Hori, A., Hixon, M. S., Kimura, H., and Miki, H. (2011) Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non- phosphorylated and phosphorylated VEGFR2 Bioorg. Med. Chem. 19, 5342-5351
44. Iwata, H., Imamura, S., Hori, A., Hixon, M. S., Kimura, H., and Miki, H. (2011) Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism Biochemistry 50, 738-751
45. Hu, Y., Furmann, N., and Bajorath, J. (2014) Current compound coverage of the kinome J. Med. Chem. DOI: 10.1021/jm5008159
46. Schloss, J. V. (1988) Significance of slow-binding enzyme inhibition and its relationship to reaction-intermediate analogues Acc. Chem. Res. 21, 348-353
47. Baici, A. (2012) Slow-onset Enzyme Inhibition and Inactivation. In Proceedings of the 5th Beilstein ESCEC Symposium, Beilstein Institute: Rüdesheim/Rhein, Germany, pp 55-73.
48. Mason, J. L., Spais, C., Husten, J., Prouty, E., Albom, M. S., Meyer, S. L., Ator, M. A., and Angeles, T. S. (2012) Comparison of LanthaScreen Eu Kinase Binding Assay and Surface Plasmon Resonance Method in Elucidating the Binding Kinetics of Focal Adhesion Kinase Inhibitors Assay Drug Dev. Technol. 10, 468-475
49. Millan, D. S., Bunnage, M. E., Burrows, J. L., Butcher, K. J., Dodd, P. G., Evans, T. J., Fairman, D. A., Hughes, S. J., Kilty, I. C., Lemaitre, A., Lewthwaite, R. A., Mahnke, A., Mathias, J. P., Philip, J., Smith, R. T., Stefaniak, M. H., Yeadon, M., and Phillips, C. (2011) Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease J. Med. Chem. 54, 7797-7814